global view constructed of white lines

Blog

PNI 2021
January 1, 2021

PNI Founders’ Message 2021

by Guest Author

Although our medical community continues to strain under the burden of COVID-19, there has been hope, determination and progress. Neurological diseases do not stop and neither have we at Pacific Neuroscience Institute.

November Clinical Trials at PNI
December 2, 2020

Clinical Trials Round-Up: December 2020

by Mini Gill

New Studies Blue Earth Diagnostics FLC-219: (PDF): An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE) (NCT04410367) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A...

7 Questions About Alzheimer's Disease Cover Image
November 25, 2020

7 Common Questions about Alzheimer’s Disease

by Guest Author

Alzheimer’s disease is a neurodegenerative condition that affects thinking, behavior and social skills. Dr. Verna Porter, Director of the Dementia, Alzheimer’s Disease and Neurocognitive Disorders Program at Pacific Brain Health Center, talked about some everyday questions that people have with regard to this disease. 1....

November Clinical Trials at PNI
November 2, 2020

Clinical Trials Round-Up: November 2020

by Mini Gill

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Clinical Trials Round Up October 2020 Cover
October 2, 2020

Clinical Trials Round-Up: October 2020

by Mini Gill

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Clinical Trials August 2020 Cover
September 1, 2020

Clinical Trials Round-Up: September 2020

by Mini Gill

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

August 25, 2020

$40 Million Gift to Pacific Brain Health Center

by Guest Author

Will & Cary Singleton Donate $40 Million to Pacific Neuroscience Institute’s Brain Health Center for Alzheimer’s Treatment & Research SANTA MONICA (July 7, 2020) –A $40 million donation from Will and Cary Singleton will support the Pacific Neuroscience Institute (PNI) Brain Health Center at Providence...

August 7, 2020

Neurology and Neurosurgery High Performance Recognized at Providence Hospitals and Affiliates

by Zara Jethani

U.S. News & World Report highlights quality, specialty care Ten Providence Southern California hospitals and affiliated partners in Los Angeles and Orange counties earned recognition on July 28, 2020, from U.S. News & World Report. With approximately 415 acute care hospitals in California, the 10...

Clinical Trials Round Up July 2020
August 4, 2020

Neuroscience Clinical Trials Round-Up: July 2020

by Mini Gill

Find out about the new and ongoing neuroscience clinical trials at Pacific Neuroscience Institute, addressing difficult diseases such as brain tumors.

ACS Chemical Neuroscience cover
June 20, 2020

When a Good Protein Goes Bad: Cdk5’s Role in Neurodegenerative Disease

by Venkata Yenugonda

Neurodegenerative disease is a broad term for a range of conditions which mostly affect neurons in the human brain. Currently, 5 million Americans suffer from Alzheimer's disease; 1 million from Parkinson's disease; and 30,000 from Huntington's disease.

Last updated: July 8th, 2020